19,008 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Acquired by Rhumbline Advisers

Rhumbline Advisers purchased a new position in Bicara Therapeutics Inc. (NASDAQ:BCAX) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 19,008 shares of the company’s stock, valued at approximately $331,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in BCAX. Spire Wealth Management purchased a new stake in shares of Bicara Therapeutics during the 4th quarter worth $31,000. SG Americas Securities LLC purchased a new stake in Bicara Therapeutics during the 4th quarter worth about $147,000. Cinctive Capital Management LP acquired a new position in shares of Bicara Therapeutics during the 3rd quarter worth about $229,000. Barclays PLC purchased a new position in shares of Bicara Therapeutics in the 3rd quarter valued at about $255,000. Finally, Jane Street Group LLC acquired a new stake in shares of Bicara Therapeutics during the 3rd quarter worth about $309,000.

Bicara Therapeutics Trading Up 5.1 %

NASDAQ BCAX opened at $16.55 on Monday. Bicara Therapeutics Inc. has a one year low of $11.10 and a one year high of $28.09. The company has a fifty day simple moving average of $13.53.

Wall Street Analyst Weigh In

BCAX has been the topic of several recent analyst reports. Wedbush reiterated an “outperform” rating and issued a $31.00 price target on shares of Bicara Therapeutics in a research note on Wednesday, February 12th. HC Wainwright lifted their target price on Bicara Therapeutics from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, January 27th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Bicara Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $41.20.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.